Comment on CMS-2026-1256-0002

Summary: SetPoint Medical Corporation expresses strong support for CMS's proposal to grant New Technology Add-on Payment (NTAP) status to its SetPoint System for treating rheumatoid arthritis. The company argues that the therapy provides significant clinical benefits, aligns with patient preferences for non-pharmacologic treatments, and offers substantial long-term cost savings for the Medicare program.